---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-012231"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:58:21.110751+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma to acquire Antev Ltd. for ~17% equity stake + up to $65M contingent milestone payments

## Summary
- Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.
- Antev shareholders eligible for up to $65M in contingent consideration tied to FDA Phase 2 and NDA approvals for Teverelix.
- Transaction expected to close before end of August 2025, subject to Antev shareholder approval and other conditions.
- Antev's lead asset Teverelix targets two indications: acute urinary retention (Phase 2b) and high-CV-risk advanced prostate cancer (Phase 2b).
- Consideration shares subject to 9-month staggered lock-up and 36-month voting agreement with Medicus management.

## SEC filing metadata
- accession: 0001062993-25-012231
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/0001062993-25-012231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-012231
- JSON: https://secwatch.observer/filing/0001062993-25-012231.json
- Plain text: https://secwatch.observer/filing/0001062993-25-012231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.